Data collection summary

Attachment 10: THRIVE Evaluation Summary

• Served 30,238 clients from 9/30/2016-9/29/2018

  • MSM of color: 10,300

  • TGW of color: 1,004

• Cross-site evaluation

  • Data used to improve programmatic performance

  • Increased identification of suboptimal performance of collaborative partners

  • Identified need for technical assistance

  • Data transmission every 6 months

    • Next data submission – 6/15/2019

  • Outcomes

• Projects funding HIV testing, must report on Numbers Tested, HIV Positivity, Knowledge of HIV-Positive Status, Late HIV Diagnosis, and Linkage to Care.

• Projects or activities where an HIV-diagnosis occurs must also collect data and report on the Housing Status of their HIV-positive clients, when applicable.

• Projects based in Medical Care settings involving efforts to provide, improve or enhance capacity for Retention in HIV Medical Care, use of Antiretroviral Therapy (ART) Among Persons in HIV Medical Care, and Viral Load Suppression among Persons in HIV Medical Care should also be reported, when applicable.

• Outputs

• All projects must report on the number of people served by the program and its core activities.

• Projects involving Training of clinical and program staff or Capacity Building with community and faith-based organizations must report the appropriate output data for these activities.

• Supplement: Screening, Brief Intervention, and Referral to Treatment (SBIRT) implementation and evaluation

  • Collaboration with SAMHSA to improve screening and referral for substance use services

  • 5 THRIVE sites participating: Baltimore, Louisiana, New York City, Philadelphia, Washington DC

  • Addiction Technology Transfer Center Network (ATTC) conducted local SBIRT trainings

    • Motivational Interviewing

    • Introduction to local SAMSHA providers

  • Evaluation of SBIRT implementation

• Collaborative Assessment Tool

  • Conducted survey of collaborative members (health department, CBOs, and clinical care providers) to assess best practices, facilitators, and barriers for developing and maintaining a community collaborative 125 surveys completed (50% response rate, thus far)

CDC THRIVE evaluation team will continue to review preliminary cross-site performance measures on a regular basis. Analyses of final cross-site evaluation database in late 2020 will provide understanding of the effectiveness of THRIVE interventions

• Special local evaluations at sites will further increase understanding of the effectiveness of THRIVE interventions

• Examples of planned evaluations:

  • Increase in PrEP providers in THRIVE jurisdicitons

  • Collaborative assessment – Collaborative Assessment Tool (survey)

  • Mapping of collaborative members to optimize reach

  • HIV testing, repeat testing, and positivity among MSM of color

  • PrEP continuum at each site

  • Effectivness of PrEP navigation models

  • HIV care continuum at each site

  • Effect of behavioral health services on the PrEP and HIV care continuums

  • PrEP initiation, adherence, and persistence in Washington DC

  • Financial incentives in New Orleans

  • Social networks of newly diagnosed HIV-positive men in Birmingham

  • ART starter packs in Baltimore, Virginia

  • Men of color served in THRIVE who weren’t MSM

  • Women of color served in THRIVE

• Timeframe for evaluation

  • Provide the start and end dates of the project period being evaluated.

Cross site evaluation data submission dates

Project Year	1st Data Submission Date	1st Data Period	2nd Data Submission Date	2nd Data Period
1 (Sep. 30, 2015 – Sep. 29, 2016)	---	---	---	---
1 (Sep. 30, 2016 – Sep. 29, 2017)	---	---	December 15, 2017	April 17, 2017 – Sep. 29, 2017
1 (Sep. 30, 2017– Sep. 29, 2018)	June 15, 2018	Sep. 30, 2017 – Mar. 31, 2018	December 15, 2018	April 17, 2018 – Sep. 29, 2018
1 (Sep. 30, 2018 – Sep. 29, 2019)	June 15, 2019	Sep. 30, 2018 – Mar. 31, 2019	December 15, 2019	April 17, 2019 – Sep. 29, 2019
No-cost extension year* (Sep. 30, 2019 – Sep. 29, 2020)**	June 15, 2020	Sep. 30, 2019 – Mar. 31, 2020	December 15, 2020**	April 17, 2020 – Sep. 29, 2020**

*Pending approval for a one year, no-cost extension

**Pending renewal of OMB approval for 5/1/ 2020 – 9/30/2020

4